Tarek Elgemmezi

Tarek Elgemmezi

Auto-generated profile, based on publicly available information

Tarek Elgemmezi

Blood Transfusion Services King Abdulaziz University Hospital Jeddah Saudi Arabia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in Transfusion
Verified
Journal Article
Closed access
SHSalwa Hindawi
Salwa Hindawi
MBMaha Badawi
Maha Badawi
RERefaat Elfayoumi
Refaat Elfayoumi
TETarek Elgemmezi
Tarek Elgemmezi
AHAbrar Al Hassani
Abrar Al Hassani
KGKholoud Gholam
Kholoud Gholam

7 February 2023 in Transfusion
Verified
Journal Article
Closed access
SHSalwa Hindawi
Salwa Hindawi
SDSundus Daghistani
Sundus Daghistani
TETarek Elgemmezi
Tarek Elgemmezi
OROsman Radhwi
Osman Radhwi
MBMaha Badawi
Maha Badawi
TMTariq A. Madani
Tariq A. Madani

8 January 2020 in Transfusion Medicine
Verified
Journal Article
Closed access
PDF file
AHAntoine Haddad
Antoine Haddad
MBMohamed Benajiba
Mohamed Benajiba
SHSlama Hmida
Slama Hmida
TETarek Elgemmezi
Tarek Elgemmezi
Mohammad A AlQudahMohammad A AlQudah
Mohammad A AlQudah
OGOlivier Garraud
Olivier Garraud

1 December 2021 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
SASaud Almalki
Saud Almalki
MAMohamed Asseri
Mohamed Asseri
YKYahya Khawaji
Yahya Khawaji
RARiad Alqurashi
Riad Alqurashi
MBMaha Badawi
Maha Badawi
SHSalwa Hindawi
Salwa Hindawi

31 December 2019 in Journal of King Abdulaziz University: Medical Sciences
Verified
Journal Article
Open access
PDF file
SASalwa A. Alnajjar
Salwa A. Alnajjar
TTTaher M. Tayeb
Taher M. Tayeb
AAAbdulrahman S. Alboog
Abdulrahman S. Alboog
TETarek M. Elgemmezi
Tarek M. Elgemmezi
SHSalwa Hindawi
Salwa Hindawi
The aim of the study is to assess the alloimmunization rate to red blood cell in thalassemia patients at King Abdulaziz University Hospital. Thalassemia is the most common genetic disorder worldwide that represents a major public health problem and requires long life blood transfusion to the patients as the main treatment. Alloimmunization to the transfused red blood cell can cause hemolytic transfusion reactions and significantly complicate transfusion therapy. Screening and identification of alloantibodies and transfusion of extended phenotyped blood can minimize these risks.A retrospective study was conducted on 134 thalassemia patients at King Abdulaziz University Hospital in Jeddah. Patients’ samples were subjected to red cell typing, antibody screening and identifi cation of red blood cell antibodies.Alloimmunization in thalassemia patients was 20.15%; antibodies were mainly to the Rh and Kell blood group systems, the highest rate was for anti-E (32.4%) followed by anti-K (21.6%). Alloimmunization rate was the highest in the age group from > 10 – 20 years (40.7%).Red cell alloimmunization is a frequent event among thalassemia patient. A national protocol for screening and identifying of the red cell alloantibodies and transfusion of phenotype blood is required for proper management of these patients.